Company: CERO
Filing Date: 2025-11-20
Form Type: 424B3
Source: 0001213900-25-113117
Chunk: 94

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-20
Form: 424B3
Chunk 94
---
 |     |             |       (147 | ) |     |            |        395 |   |     |            |  268.7 | %  |
| Change in fair value of earnout and derivative liabilities |     |                            |           — |   |     |             |    170,000 |   |     |            |    170,000 |   |     |            | (100.0 | )% |
| Write off of deferred offering costs                       |     |                            |    (500,000 | ) |     |             |          - |   |     |            |   (500,000 | ) |     |            | (100.0 | )% |
| Interest income (expense), net                             |     |                            |       5,936 |   |     |             |      4,418 |   |     |            |      1,518 |   |     |            |   34.4 | %  |
| Total other income (expense), net                          |     |                            |    (493,816 | ) |     |             |    174,271 |   |     |            |   (668,087 | ) |     |            | (383.4 | )% |
| Net loss                                                   |     |                            |  (4,856,395 | ) |     |             | (4,227,967 | ) |     |            |   (628,428 | ) |     |            |   14.9 | %  |
| Deemed dividend on Series D Preferred Stock                |     |                            |  (6,649,828 | ) |     |             |          — |   |     |            | (6,649,828 | ) |     |            |  100.0 | %  |
| Net loss attributable to common stockholders               |     | $                          | (11,506,223 | ) |     | $           | (4,227,967 | ) |     | $          | (7,278,256 | ) |     |            |  172.1 | %  |

Research and Development Expenses

Research and development
expenses were $2,386,000 for the three months ended September 30, 2025 as compared to $1,774,000 for the three months ended September
30, 2024, reflecting an increase of $612,000. The increase was primarily attributable to an increase in